Abrocitinib
- Generic Name
- Abrocitinib
- Brand Names
- Cibinqo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H21N5O2S
- CAS Number
- 1622902-68-4
- Unique Ingredient Identifier
- 73SM5SF3OR
- Background
Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function. The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of aut...
- Indication
Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the US, it is indicated to treat refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inad...
- Associated Conditions
- Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, refractory Atopic dermatitis, Refractory, severe Atopic Dermatitis
- Associated Therapies
- -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT05038982
- Locations
- 🇺🇸
Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04564755
- Locations
- 🇺🇸
Beach Allergy and Asthma Specialty Group, A Medical Corporation, Long Beach, California, United States
🇺🇸Cahaba Dermatology and Skin Health Center, Birmingham, Alabama, United States
🇺🇸Antelope Valley Clinical Trials, Lancaster, California, United States
Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT04099563
- Locations
- 🇨🇳
Beijing Hospital Sub-Center of Beijing Hospital Clinical Trial & Research Center, Beijing, China
A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03937258
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03806101
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 287
- Registration Number
- NCT03796676
- Locations
- 🇺🇸
UC Davis, Sacramento, California, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Madera Family Medical Group, Madera, California, United States
Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03796182
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT03742336
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT03662516
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Renal Impairment Study for PF-04965842
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT03660241
- Locations
- 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.